Literature DB >> 25923944

Tumor size is not a criterion for resection during the management of giant hemangioma of the liver.

Jian Dong1, Meng Zhang, Jia-qi Chen, Feng Ma, Hao-hua Wang, Yi Lv.   

Abstract

BACKGROUND: Liver hemangiomas are the most common benign liver tumors. The management of giant (≥5 cm) hemangioma of the liver remains controversial. The aim of this study was to assess the influence of tumor size on postoperative outcomes after hepatectomy in patients with giant hemangioma of the liver.
METHODS: Patients who were subjected to resection because of giant liver hemangioma between December 2006 and July 2012 were grouped by largest tumor size: 5-10 cm (group A) and 10-15 cm (group B). All patients underwent detailed preoperative assessments. Clinicopathologic features were analyzed, and univariate and multivariate analyses were used to determine risk factors that correlated independently with any complication, as well as the intraoperative red blood cell transfusion requirement. Long-term outcomes were assessed with a median follow-up of 56 months.
RESULTS: One hundred and ninety patients, mean age 46 years, were included. The 146 patients with tumors 5-10 cm in size were compared with the remaining 44 patients with tumors 5-10 cm in size. The differences in postoperative morbidity (29.86 vs. 41.30%, P=0.150) and duration of hospitalization (11.06±7.02 vs. 12.17±7.74, P=0.465) between group A and group B did not reach statistical significance. Operation time, blood loss, and transfusion volume of group B were greater than those of group A. No perioperative deaths occurred and no recurrences were registered during follow-up in both groups. The results of univariate and multivariate analysis showed that diameter was not an independent risk factor of postoperative complications and intraoperative red blood cell transfusion.
CONCLUSION: Giant hemangiomas should be monitored regularly. Asymptomatic tumors 5-10 cm in diameter can be managed conservatively even though they grow. When necessary, surgical treatment can be well justified because of low morbidity and mortality.

Entities:  

Mesh:

Year:  2015        PMID: 25923944     DOI: 10.1097/MEG.0000000000000344

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  The surgical outcomes and risk factors of giant hepatic haemangiomas: a single centre experience.

Authors:  Zhitao Dong; Kunpeng Fang; Chengjun Sui; Junwu Guo; Binghua Dai; Li Geng; Jiamei Yang
Journal:  BMC Surg       Date:  2022-07-17       Impact factor: 2.030

2.  Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study.

Authors:  Tengqian Tang; Xishu Wang; Yilei Mao; Jing Li; Tianfu Wen; Weidong Jia; Yongjun Chen; Tao Peng; Lingxiao Liu; Ruifang Fan; Kuansheng Ma; Feng Xia
Journal:  Ann Transl Med       Date:  2021-07

3.  Surgical Management of Giant Hepatic Hemangioma: Single Center's Experience with 144 Patients.

Authors:  Mohamed Abdel Wahab; Ayman El Nakeeb; Mahmoud Abdelwahab Ali; Youssef Mahdy; Ahmed Shehta; Mohamed Abdulrazek; Mohamed El Desoky; Rihame Abdel Wahab
Journal:  J Gastrointest Surg       Date:  2018-02-27       Impact factor: 3.452

4.  Giant Liver Hemangiomas: A Plea for Early Surgical Referral and Resection.

Authors:  Alvin Chang; Brianna Ruch; Aamir Khan; Marlon Levy; Amit Sharma
Journal:  Case Rep Surg       Date:  2020-06-16

5.  Liver transplantation for giant hemangioma of the liver: A case report and review of the literature.

Authors:  Yun Zhao; Xiu-Ping Li; Yuan-Yuan Hu; Ji-Chang Jiang; Li-Jin Zhao
Journal:  Front Med (Lausanne)       Date:  2022-09-15

6.  Predictive value of alarm symptoms in patients with Rome IV dyspepsia: A cross-sectional study.

Authors:  Zhong-Cao Wei; Qian Yang; Qi Yang; Juan Yang; Xin-Xing Tantai; Xin Xing; Cai-Lan Xiao; Yang-Lin Pan; Jin-Hai Wang; Na Liu
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.